BLTE vs. OGN, NUVL, BBIO, ALKS, APLS, RNA, CRNX, AXSM, PRGO, and RARE
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Organon & Co. (OGN), Nuvalent (NUVL), BridgeBio Pharma (BBIO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), Perrigo (PRGO), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical preparations" industry.
Belite Bio (NASDAQ:BLTE) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.
Belite Bio presently has a consensus price target of $54.75, suggesting a potential upside of 11.42%. Organon & Co. has a consensus price target of $22.60, suggesting a potential upside of 1.76%. Given Belite Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Belite Bio is more favorable than Organon & Co..
In the previous week, Organon & Co. had 5 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for Organon & Co. and 2 mentions for Belite Bio. Organon & Co.'s average media sentiment score of 0.87 beat Belite Bio's score of 0.29 indicating that Organon & Co. is being referred to more favorably in the news media.
Belite Bio received 9 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 96.15% of users gave Belite Bio an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
0.5% of Belite Bio shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 1.4% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Organon & Co. has a net margin of 16.50% compared to Belite Bio's net margin of 0.00%. Belite Bio's return on equity of -44.15% beat Organon & Co.'s return on equity.
Organon & Co. has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Belite Bio has a beta of -1.47, indicating that its stock price is 247% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
Summary
Organon & Co. beats Belite Bio on 10 of the 17 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
Buy BLTE with Qtrade Free BLTE Stock Alerts